Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Domestic Vaccine Market Showing Strong Growth
November 15, 2011
- Sawai President to Increase “Hospital MRs” to 100
November 15, 2011
- CMIC to Develop Orphan Drugs With Partners, Funds: Chairman Nakamura
November 15, 2011
- Bayer Yakuhin Modifies Storage Conditions for Kogenate FS for Home Use
November 15, 2011
- EPS: Solid Growth in Sales, Profits Driven by SMO, CSO Businesses
November 15, 2011
- Otsuka Draws Up Strategy in Anticipation of Abilify Patent Expiration
November 14, 2011
- Otsuka Forms Alliance with Lundbeck in CNS Field
November 14, 2011
- Astellas Completes Recombinant Flu Vaccine Inoculation of Subjects of PII Trials
November 14, 2011
- SymBio Initiates Domestic PII Clinical Trials of Bendamustine for Add’l Indications
November 14, 2011
- Pharmaceutical Sales Down 2.2 % due to Decrease in Sales of Elplat: Yakult
November 14, 2011
- Antibody Drugs to Support Kyowa Kirin’s Growth Over Next 10 Years: Dr Oshima
November 14, 2011
- Sawai’s Sales Up 4.3%, Showed Sluggish Growth Due to Break in Positive Impact of 2010 Premium Revision
November 14, 2011
- Rohto: Sales, Profits Driven By Growth in Asian Market
November 14, 2011
- Favorable Results from PII Trial of Ono’s Ca Receptor Agonist Announced in US
November 14, 2011
- Meiji HD: Pharmaceutical Sales Up 1% in Apr-Sep on Reflex Growth
November 11, 2011
- Top-3 GE Makers Report 10.4% Increase in Sales; Pace Down from Year Before
November 11, 2011
- Otsuka HD: Pharmaceutical Sales Up 1.7% in Apr-Sep Driven by Abilify
November 11, 2011
- President of Sawai Expects Generic Use Promotion in Next Medical Fee Revision
November 11, 2011
- Daiichi Sankyo Introduces AKT Inhibitor from US Firm, Obtains License Worldwide
November 11, 2011
- Ono to Restructure for Stronger Research Support System
November 11, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…